# US 2019/0314345 A1 · Calcineurin inhibitor and non-steroidal anti-inflammatory drug to reduce risk of post-imaging pancreatitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314345 A1
- Document ID: US20190314345A1
- Status: Published application
- Kind: A1
- Application number: 16/393,531
- Filed: 2019-04-24
- Published: 2019-10-17
- Earliest claimed: 2016-10-26
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - of the Commonwealth System of Higher Education
- Inventors: Sohail HUSAIN
- Web page: https://patentgrep.com/patent/US20190314345A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 38/13: Cyclosporins
- A61K 49/0404: {containing barium sulfate}
- A61K 49/0438: {Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol}
- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 39/00: General protective or antinoxious agents
- A61F 2/82: Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07)
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/426: Immunomodulating agents, i.e. cytokines, interleukins, interferons
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

The present invention relates to compositions and methods for targeted administration to the pancreas of a calcineurin inhibitor and a non-steroidal anti-inflammatory drug (“NSAID”) to reduce the risk and/or limit the extent of post-imaging pancreatitis associated with procedures that employ a radiocontrast medium, particularly procedures that selectively image the pancreas, gallbladder and/or biliary tree.

## Claims

### Claim 1

A radiocontrast medium comprising effective amounts of: (i) a radiocontrast agent; (ii) a calcineurin inhibitor; and (iii) a NSAID.

### Claim 2 (depends on 1)

The radiocontrast medium of claim 1, where the calcineurin inhibitor is FK506.

### Claim 3 (depends on 1)

The radiocontrast medium of claim 1, where the calcineurin inhibitor is cyclosporine.

### Claim 4 (depends on 1)

The radiocontrast medium of claim 1, where the NSAID is indomethacin.

### Claim 5

A kit comprising a radiocontrast medium comprising: (i) a radiocontrast agent; (ii) a calcineurin inhibitor; and (iii) a NSAID.

### Claim 6 (depends on 5)

The kit of claim 5, where the calcineurin inhibitor is FK506.

### Claim 7 (depends on 5)

The kit of claim 5, where the calcineurin inhibitor is cyclosporine.

### Claim 8 (depends on 5)

The kit of claim 5, where the NSAID is indomethacin.

### Claim 9 (depends on 5)

The kit of claim 5, further comprising a stent.

### Claim 10

A pharmaceutical composition comprising effective amounts of (i) a calcineurin inhibitor and (ii) a NSAID in a pharmaceutically suitable excipient.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10 which is an aqueous solution or emulsion.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10 which is a suppository.

### Claim 13 (depends on 10)

The pharmaceutical composition of claim 10, wherein the calcineurin inhibitor is FK506.

### Claim 14 (depends on 10)

The pharmaceutical composition of claim 10, wherein the calcineurin inhibitor is cyclosporine.

### Claim 15 (depends on 10)

The pharmaceutical composition of claim 10, wherein the NSAID is indomethacin.

### Claim 16 (depends on 10)

A kit comprising the pharmaceutical composition of claim 10, further containing a stent.

### Claim 17

A method for reducing the risk or extent of post-imaging pancreatitis in a subject in need of such treatment, comprising administering, to the subject, a radiocontrast medium comprising effective amounts of a radiocontrast agent, a calcineurin inhibitor, and a NSAID.

### Claim 18 (depends on 17)

The method of claim 17, wherein the calcineurin inhibitor is FK506.

### Claim 19 (depends on 17)

The method of claim 17, wherein the calcineurin inhibitor is cyclosporine.

### Claim 20 (depends on 17)

The method of claim 17, wherein the NSAID is indomethacin.

### Claim 21 (depends on 17)

The method of claim 17, further comprising administering to the subject a pharmaceutical composition that does not contain radiocontrast medium but comprises an effective amount of a calcineurin inhibitor and a NSAID.

### Claim 22 (depends on 21)

The method of claim 21, wherein the calcineurin inhibitor is FK506.

### Claim 23 (depends on 21)

The method of claim 21, wherein the calcineurin inhibitor is cyclosporine.

### Claim 24 (depends on 21)

The method of claim 21, wherein the NSAID is indomethacin.

### Claim 25 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition is introduced via a pancreatic stent.

### Claim 26

A method for reducing the risk or extent of post-imaging pancreatitis in a subject in need of such treatment, comprising administering, to the subject, a pharmaceutical composition that does not contain radiocontrast medium but comprises effective amounts of a calcineurin inhibitor and a NSAID.

### Claim 27 (depends on 26)

The method of claim 26, wherein the calcineurin inhibitor is FK506.

### Claim 28 (depends on 26)

The method of claim 26, wherein the calcineurin inhibitor is cyclosporine.

### Claim 29 (depends on 26)

The method of claim 26, wherein the NSAID is indomethacin.

### Claim 30

A method for reducing the risk or extent of post-imaging pancreatitis in a subject in need of such treatment, comprising introducing, into the subject, a pancreatic stent having a coating on at least a portion of one surface comprising a calcineurin inhibitor and a NSAID.

### Claim 31 (depends on 30)

The method of claim 30, wherein the calcineurin inhibitor is FK506.

### Claim 32 (depends on 30)

The method of claim 30, wherein the calcineurin inhibitor is cyclosporine.

### Claim 33 (depends on 30)

The method of claim 30, wherein the NSAID is indomethacin.

### Claim 34

A radiocontrast medium comprising effective amounts of a radiocontrast agent, a calcineurin inhibitor, and a NSAID, for use in reducing the risk or extent of post-imaging pancreatitis in a subject.

### Claim 35 (depends on 34)

The medium of claim 34, wherein the calcineurin inhibitor is FK506.

### Claim 36 (depends on 34)

The medium of claim 34, wherein the calcineurin inhibitor is cyclosporine.

### Claim 37 (depends on 34)

The medium of claim 34, wherein the NSAID is indomethacin.

### Claim 38

A pharmaceutical composition that does not contain radiocontrast medium but comprises an effective amount of a calcineurin inhibitor and a NSAID, for use in reducing the risk or extent of post-imaging pancreatitis in a subject.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the calcineurin inhibitor is FK506.

### Claim 40 (depends on 38)

The composition of claim 38, wherein the calcineurin inhibitor is cyclosporine.

### Claim 41 (depends on 38)

The composition of claim 38, wherein the NSAID is indomethacin.

### Claim 42 (depends on 38)

The composition of claim 38, wherein the pharmaceutical composition is introduced via a pancreatic stent.

### Claim 43

A stent for placement in a pancreas having a coating on at least a portion of one surface, said coating comprising effective amount(s) of a calcineurin inhibitor and/or NSAID.

### Claim 44 (depends on 43)

The stent of claim 43, wherein the calcineurin inhibitor is FK506.

### Claim 45 (depends on 43)

The stent of claim 43, wherein the calcineurin inhibitor is cyclosporine.

### Claim 46 (depends on 43)

The stent of claim 43, wherein the NSAID is indomethacin.

### Claim 47 (depends on 43)

The stent of claim 43, for use in reducing the risk or extent of post-imaging pancreatitis in a subject.
